To join this case, fill out the form below
Prometheus Biosciences, Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Prometheus Biosciences, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Prometheus Biosciences, Inc. (“Prometheus” or the “Company”) (NASDAQ: RXDX), in connection with its acquisition by Merck & Co., Inc. (NYSE: MRK).  Under the merger agreement, Prometheus shareholders will receive $200.00 cash per share.  The transaction value is approximately $10.8 billion.

Weiss Law is investigating whether (i) Prometheus’ board acted in the best interests of Company shareholders in agreeing to the merger, (ii) the per share merger consideration adequately compensates Prometheus’ shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Other Cases

January 2, 2024

Via Renewables, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Via Renewables, Inc. (“Via” or the “Company”) (NASDAQ: VIA), in connection with its acquisition by Retailco, LLC. Under the merger agreement, the Company’s shareholders will receive $11.00 per share.

Join Case →

December 26, 2023

RayzeBio, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of RayzeBio, Inc. (“RayzeBio” or the “Company”) (NASDAQ: RYZB), in connection with its acquisition by Bristol Myers Squibb Company (NYSE: BMY) via tender offer. Under the merger agreement, the Company’s shareholders will receive $62.50 per share. The transaction is valued at approximately $14.1 billion.

Join Case →

December 26, 2023

Karuna Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Karuna Therapeutics, Inc. (“Karuna” or the “Company”) (NASDAQ: KRTX), in connection with its acquisition by Bristol Myers Squibb Company (NYSE: BMY) . Under the merger agreement, the Company’s shareholders will receive $330.00 per share. The transaction is valued at approximately $14.0 billion.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn